{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:28:47Z","timestamp":1792610927500,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T00:00:00Z","timestamp":1365465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40520-013-0031-z","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T06:46:58Z","timestamp":1365403618000},"page":"129-137","source":"Crossref","is-referenced-by-count":21,"title":["Chronic gout in the elderly"],"prefix":"10.1007","volume":"25","author":[{"given":"Francesco","family":"Bolzetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,9]]},"reference":[{"key":"31_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub R (2010) Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6:30\u201338","journal-title":"Nat Rev Rheumatol"},{"key":"31_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-007-0421-7","volume":"28","author":"F Leonardis De","year":"2007","unstructured":"De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F (2007) Elderly-onset gout: a review. Rheumatol Int 28:1\u20136","journal-title":"Rheumatol Int"},{"key":"31_CR3","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez G, Soriano LC, Choi HK (2010) Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 69:2090\u20132094","DOI":"10.1136\/ard.2010.130013"},{"key":"31_CR4","unstructured":"Rose BR, Becker MA (2005) Uric acid renal disease. http:\/\/patients.uptodate.com\/topic.asp?file=renldis\/13851&title=Gout . Accessed 9 June 2005"},{"key":"31_CR5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MJT.0b013e3181df8ad2","volume":"17","author":"A Whelton","year":"2010","unstructured":"Whelton A (2010) Current and future therapeutic options for the management of gout. Am J Ther 17:402\u2013417","journal-title":"Am J Ther"},{"key":"31_CR6","first-page":"549","volume":"106","author":"AK Tausche","year":"2009","unstructured":"Tausche AK, Jansen TL, Schr\u00f6der HE, Bornstein SR, Aringer M, M\u00fcller-Ladner U (2009) Gout-current diagnosis and treatment. Dtsch Arztebl Int 106:549\u2013555","journal-title":"Dtsch Arztebl Int"},{"key":"31_CR7","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.1973.03220230017005","volume":"224","author":"JL Katz","year":"1973","unstructured":"Katz JL, Weiner H, Gutman A et al (1973) Hyperuricemia, gout, and the executive suite. JAMA 224:1251\u20131257","journal-title":"JAMA"},{"key":"31_CR8","doi-asserted-by":"crossref","unstructured":"Bolzetta F, Veronese N, Mosele M, Sergi G, Manzato E, Giantin V (2012) A case of naturally evolving gout in an elderly man. Arch Gerontol Geriatr 55:497\u2013498","DOI":"10.1016\/j.archger.2011.09.002"},{"key":"31_CR9","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, O\u2019Fallon WM, Gabriel SE (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403\u20132406","journal-title":"J Rheumatol"},{"key":"31_CR10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0889-857X(21)00887-5","volume":"16","author":"R Roubenoff","year":"1990","unstructured":"Roubenoff R (1990) Gout and hyperuricemia. Rheum Dis Clin North Am 16:539\u2013550","journal-title":"Rheum Dis Clin North Am"},{"issue":"9","key":"31_CR11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0895-4356(94)00244-K","volume":"48","author":"CM Harris","year":"1995","unstructured":"Harris CM, Lloyd DC, Lewis J (1995) The prevalence and prophylaxis of gout in England. J Clin Epidemiol 48(9):1153\u20131158","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"31_CR12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/ard.2007.076232","volume":"67","author":"L Annemans","year":"2008","unstructured":"Annemans L, Spaepen E, Gaskin M et al (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000\u20132005. Ann Rheum Dis 67(7):960\u2013966","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"31_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","volume":"64","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB et al (2005) Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999. Ann Rheum Dis 64(2):267\u2013272","journal-title":"Ann Rheum Dis"},{"key":"31_CR14","first-page":"1582","volume":"31","author":"KL Wallace","year":"2004","unstructured":"Wallace KL, Riedel AA, Joseph-Ridge N et al (2004) Increasing prevalence of gout and hyperuricemia over 10\u00a0years among older adults in a managed care population. J Rheumatol 31:1582\u20131587","journal-title":"J Rheumatol"},{"key":"31_CR15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/rheumatology\/kep086","volume":"48","author":"M Doherty","year":"2009","unstructured":"Doherty M (2009) New insights into the epidemiology of gout. Rheumatology 48:2\u20138","journal-title":"Rheumatology"},{"key":"31_CR16","doi-asserted-by":"crossref","unstructured":"Saag KG, Choi H (2006) Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 8:S1\u2013S2","DOI":"10.1186\/ar1907"},{"key":"31_CR17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000321074","volume":"30","author":"M Kanbay","year":"2010","unstructured":"Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A (2010) Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif 30:288\u2013295","journal-title":"Blood Purif"},{"key":"31_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2458-11-101","volume":"11","author":"H Bussche van den","year":"2011","unstructured":"van den Bussche H, Koller D, Kolonko T et al (2011) Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany. BMC Publ Health 11:101","journal-title":"BMC Publ Health"},{"key":"31_CR19","doi-asserted-by":"crossref","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali M, Kanellis J, Han L et al (2002) Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:F991\u2013F997","journal-title":"Am J Physiol Renal Physiol"},{"key":"31_CR20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/CIRCULATIONAHA.108.191261","volume":"119","author":"D Lloyd-Jones","year":"2009","unstructured":"Lloyd-Jones D, Adams R, Carnethon M et al (2009) Heart disease and stroke statistics\u20142009 update a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:e21\u2013e181","journal-title":"Circulation"},{"key":"31_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2009.2014","volume":"303","author":"KM Flegal","year":"2010","unstructured":"Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999\u20132008. JAMA 303:235\u2013241","journal-title":"JAMA"},{"key":"31_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","volume":"41","author":"RD Abbott","year":"1988","unstructured":"Abbott RD, Brand FN, Kannel WB, Castelli WP (1988) Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 41:237\u2013242","journal-title":"J Clin Epidemiol"},{"key":"31_CR23","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1001\/jama.291.23.2847","volume":"291","author":"AA Hedley","year":"2004","unstructured":"Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999\u20132002. JAMA 291:2847\u20132850","journal-title":"JAMA"},{"key":"31_CR24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1467-789X.2003.00107.x","volume":"4","author":"EM Inelmen","year":"2003","unstructured":"Inelmen EM, Sergi G, Coin A, Miotto F, Peruzza S, Enzi G (2003) Can obesity be a risk factor in elderly people? Obes Rev 4:147\u2013155","journal-title":"Obes Rev"},{"key":"31_CR25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM, American College of Physicians; American Physiological Society (2005) Pathogenesis of gout. Ann Intern Med 143:499\u2013516","journal-title":"Ann Intern Med"},{"key":"31_CR26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/ard.59.7.539","volume":"59","author":"PH Dessein","year":"2000","unstructured":"Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J (2000) Beneficial effects of weight loss associated with moderate calorie\/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59:539\u2013543","journal-title":"Ann Rheum Dis"},{"key":"31_CR27","first-page":"43","volume":"121","author":"R Suppiah","year":"2008","unstructured":"Suppiah R, Dissanayake A, Dalbeth N (2008) High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J 121:43\u201350","journal-title":"N Z Med J"},{"key":"31_CR28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00296-009-1304-x","volume":"31","author":"HG Yoo","year":"2011","unstructured":"Yoo HG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH (2011) Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int 31:485\u2013491","journal-title":"Rheumatol Int"},{"key":"31_CR29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/RHU.0b013e3181c6802e","volume":"16","author":"T Inokuchi","year":"2010","unstructured":"Inokuchi T, Tsutsumi Z, Takahashi S, Ka T, Moriwaki Y, Yamamoto T (2010) Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout. J Clin Rheumatol 16:109\u2013112","journal-title":"J Clin Rheumatol"},{"key":"31_CR30","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1001\/jama.1991.03470210076036","volume":"266","author":"F Facchini","year":"1991","unstructured":"Facchini F, Chen YD, Holleeck CB, Reaven GM (1991) Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008\u20133011","journal-title":"JAMA"},{"key":"31_CR31","first-page":"1","volume":"5","author":"RB Ervin","year":"2009","unstructured":"Ervin RB (2009) Prevalence of metabolic syndrome among adults 20\u00a0years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003\u20132006. Natl Health Stat Rep 5:1\u20137","journal-title":"Natl Health Stat Rep"},{"key":"31_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00360-008-0291-7","volume":"179","author":"RJ Johnson","year":"2009","unstructured":"Johnson RJ, Sautin YY, Oliver WJ et al (2009) Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B 179:67\u201376","journal-title":"J Comp Physiol B"},{"key":"31_CR33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0002-9343(75)90222-3","volume":"59","author":"L Berger","year":"1975","unstructured":"Berger L, Y\u00fc TF (1975) Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 59:605\u2013613","journal-title":"Am J Med"},{"key":"31_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000168799","volume":"15","author":"DC Tarng","year":"1995","unstructured":"Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP (1995) Renal function in gout patients. Am J Nephrol 15:31\u201337","journal-title":"Am J Nephrol"},{"key":"31_CR35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1291\/hypres.24.691","volume":"24","author":"K Iseki","year":"2001","unstructured":"Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24:691\u2013697","journal-title":"Hypertens Res"},{"key":"31_CR36","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","volume":"13","author":"DH Kang","year":"2002","unstructured":"Kang DH, Nakagawa T, Feng L, Watanabe S et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888\u20132897","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"31_CR37","first-page":"233","volume":"24","author":"J V\u00e1zquez-Mellado","year":"2006","unstructured":"V\u00e1zquez-Mellado J, Cruz J, Guzm\u00e1n S et al (2006) Severe tophaceous gout. Characterization of low socioeconomic level patients from Mexico. Clin Exp Rheumatol 24(3):233\u2013238","journal-title":"Clin Exp Rheumatol"},{"key":"31_CR38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038\u20132047","journal-title":"JAMA"},{"key":"31_CR39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.RHU.0000049713.85784.ED","volume":"9","author":"KT Rott","year":"2003","unstructured":"Rott KT, Holland NW, Agudelo CA (2003) Blister as the initial presentation of gout. J Clin Rheumatol 9:41\u201342","journal-title":"J Clin Rheumatol"},{"key":"31_CR40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0002-9343(74)90847-X","volume":"57","author":"MA Manuel","year":"1974","unstructured":"Manuel MA, Steele TH (1974) Changes in renal urate handling after prolonged thiazide treatment. Am J Med 57:741\u2013746","journal-title":"Am J Med"},{"key":"31_CR41","first-page":"305","volume":"8","author":"AM Kahn","year":"1988","unstructured":"Kahn AM (1988) Effect of diuretics on the renal handling of urate. Semin Nephrol 8:305","journal-title":"Semin Nephrol"},{"key":"31_CR42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archinte.1987.00370040027005","volume":"147","author":"HG Langford","year":"1987","unstructured":"Langford HG, Blaufox MD, Borhani NO et al (1987) Is thiazide produced uric acid elevation harmful? Arch Intern Med 147:645\u2013649","journal-title":"Arch Intern Med"},{"key":"31_CR43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/ard.51.2.259","volume":"51","author":"JT Scott","year":"1992","unstructured":"Scott JT, Higgen CS (1992) Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 51:259\u2013261","journal-title":"Ann Rheum Dis"},{"key":"31_CR44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0895-4356(97)00101-7","volume":"50","author":"JH Gurwitz","year":"1997","unstructured":"Gurwitz JH, Kalish SC, Bohn RL et al (1997) Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50:953\u2013959","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"31_CR45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archinte.1987.00370040027005","volume":"147","author":"HG Langford","year":"1987","unstructured":"Langford HG, Blaufox MD, Borhani NO et al (1987) Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 147(4):645\u2013649","journal-title":"Arch Intern Med"},{"issue":"8","key":"31_CR46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI103905","volume":"38","author":"TF Yu","year":"1959","unstructured":"Yu TF, Gutman AB (1959) Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 38(8):1298\u20131315","journal-title":"J Clin Invest"},{"key":"31_CR47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C","volume":"43","author":"D Caspi","year":"2000","unstructured":"Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R (2000) The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 43:103\u2013108","journal-title":"Arthritis Rheum"},{"key":"31_CR48","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2165\/00003495-200565180-00004","volume":"65","author":"L Stamp","year":"2005","unstructured":"Stamp L, Searle M, O\u2019Donnell J, Chapman P (2005) Gout in solid organ transplantation: a challenging clinical problem. Drugs. 65:2593\u20132611","journal-title":"Drugs."},{"key":"31_CR49","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/TP.0b013e318222ca2f","volume":"27","author":"C Boesmueller","year":"2011","unstructured":"Boesmueller C, Biebl M, Scheidl S et al (2011) Long-term outcome in kidney transplant recipients over 70\u00a0years in the Eurotransplant Senior Kidney Transplant Program: a single center experience. Transplantation 27:210\u2013216","journal-title":"Transplantation"},{"key":"31_CR50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2007.05.003","volume":"64","author":"V Pumo","year":"2007","unstructured":"Pumo V, Sciacca D, Malaguarnera M (2007) Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol 64:31\u201342","journal-title":"Crit Rev Oncol Hematol"},{"key":"31_CR51","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/rheumatology\/ken305","volume":"47","author":"HK Choi","year":"2008","unstructured":"Choi HK, De Vera MA, Krishnan E (2008) Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 47:1567\u20131570","journal-title":"Rheumatology"},{"key":"31_CR52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1079\/BJN20051456","volume":"94","author":"C Bamia","year":"2005","unstructured":"Bamia C, Orfanos P, Ferrari P et al (2005) Dietary patterns among older Europeans: the EPIC-Elderly study. Br J Nutr 94:100\u2013113","journal-title":"Br J Nutr"},{"key":"31_CR53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2011.06.003","volume":"70","author":"C Chrysohoou","year":"2011","unstructured":"Chrysohoou C, Skoumas J, Pitsavos C et al (2011) Long-term adherence to the Mediterranean diet reduces the prevalence of hyperuricaemia in elderly individuals, without known cardiovascular disease: the Ikaria study. Maturitas. 70:58\u201364","journal-title":"Maturitas."},{"key":"31_CR54","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2169\/internalmedicine.50.5506","volume":"50","author":"Y Nishida","year":"2011","unstructured":"Nishida Y, Iyadomi M, Higaki Y et al (2011) Influence of physical activity intensity and aerobic fitness on the anthropometric index and serum uric acid concentration in people with obesity. Intern Med 50:2121\u20132128","journal-title":"Intern Med"},{"key":"31_CR55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","volume":"375","author":"P Richette","year":"2010","unstructured":"Richette P, Bardin T (2010) Gout. Lancet 375:318\u2013328","journal-title":"Lancet"},{"key":"31_CR56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","volume":"82","author":"EW Campion","year":"1987","unstructured":"Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82:421\u2013426","journal-title":"Am J Med"},{"key":"31_CR57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11926-011-0162-1","volume":"13","author":"Faranak Ghaemi-Oskouie","year":"2011","unstructured":"Ghaemi-Oskouie Faranak, Shi Yan (2011) The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 13:160\u2013166","journal-title":"Curr Rheumatol Rep"},{"key":"31_CR58","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/1529-0131(200008)43:8<1779::AID-ANR14>3.0.CO;2-2","volume":"43","author":"DR Yagnik","year":"2000","unstructured":"Yagnik DR, Hillyer P, Marshall D et al (2000) Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout. Arthritis Rheum 43:1779\u20131789","journal-title":"Arthritis Rheum"},{"key":"31_CR59","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.1780340716","volume":"34","author":"R Terkeltaub","year":"1991","unstructured":"Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K (1991) Monocyte-derived neutrophil chemotactic factor\/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 34:894\u2013903","journal-title":"Arthritis Rheum"},{"key":"31_CR60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237\u2013241","journal-title":"Nature"},{"key":"31_CR61","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/art.27356","volume":"62","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth N, Pool B, Gamble GD et al (2010) Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 62:1549\u20131556","journal-title":"Arthritis Rheum"},{"key":"31_CR62","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clindermatol.2006.07.015","volume":"24","author":"GF Falasca","year":"2006","unstructured":"Falasca GF (2006) Metabolic diseases: gout. Clin Dermatol 24:498\u2013508","journal-title":"Clin Dermatol"},{"key":"31_CR63","unstructured":"Fedele D (2003) Gotta ed iperuricemie, 2nd edn. Idelson-Gnocchi, Naples"},{"key":"31_CR64","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.3949\/ccjm.75.Suppl_5.S13","volume":"75","author":"NL Edwards","year":"2008","unstructured":"Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 75:S13\u2013S16","journal-title":"Cleve Clin J Med"},{"key":"31_CR65","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"CY Hsu","year":"2009","unstructured":"Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169:342\u2013350","journal-title":"Arch Intern Med"},{"key":"31_CR66","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5435\/00124635-200710000-00007","volume":"15","author":"BT Fitzgerald","year":"2007","unstructured":"Fitzgerald BT, Setty A, Mudgal CS (2007) Gout affecting the hand and wrist. J Am Acad Orthop Surg 15:625\u2013635","journal-title":"J Am Acad Orthop Surg"},{"key":"31_CR67","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","volume":"26","author":"RA Brook","year":"2010","unstructured":"Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N (2010) Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 26:2813\u20132821","journal-title":"Curr Med Res Opin"},{"key":"31_CR68","doi-asserted-by":"crossref","unstructured":"Bolzetta F, Veronese N, Mosele M, Sergi G, Manzato E (2012) Tophaceous gout in the elderly: a clinical case review. Clin Rheumatol 31:1127\u20131132","DOI":"10.1007\/s10067-012-1956-x"},{"key":"31_CR69","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3949\/ccjm.75.Suppl_5.S5","volume":"75","author":"BF Mandell","year":"2008","unstructured":"Mandell BF (2008) Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 75:S5\u2013S8","journal-title":"Cleve Clin J Med"},{"key":"31_CR70","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","volume":"50","author":"D Rothenbacher","year":"2011","unstructured":"Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodr\u00edguez LA (2011) Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology 50:973\u2013981","journal-title":"Rheumatology"},{"key":"31_CR71","unstructured":"Schlesinger N (2005) Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 11, S443\u201350 (quiz S465\u20138)"},{"key":"31_CR72","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3899\/jrheum.091385","volume":"37","author":"I Pel\u00e1ez-Ballestas","year":"2010","unstructured":"Pel\u00e1ez-Ballestas I (2010) Hern\u00e1ndez Cuevas C, Burgos-Vargas R, et al. Diagnosis of chronic gout: evaluating the American College of Rheumatology proposal, European league against rheumatism recommendations, and clinical judgment. J Rheumatol 37:1743\u20131748","journal-title":"J Rheumatol"},{"key":"31_CR73","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E et al (2006) EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301\u20131311","journal-title":"Ann Rheum Dis"},{"key":"31_CR74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e328335ef38","volume":"22","author":"HK Choi","year":"2010","unstructured":"Choi HK (2010) A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 22:165\u2013172","journal-title":"Curr Opin Rheumatol"},{"key":"31_CR75","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","volume":"68","author":"JA Singh","year":"2009","unstructured":"Singh JA, Hodges JS, Asch SM (2009) Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 68:1265\u20131270","journal-title":"Ann Rheum Dis"},{"key":"31_CR76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/BOR.0b013e328325bd94","volume":"21","author":"S Chohan","year":"2009","unstructured":"Chohan S, Becker MA (2009) Update on emerging urate-lowering therapies. Curr Opin Rheumatol 21:143\u2013149","journal-title":"Curr Opin Rheumatol"},{"key":"31_CR77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/kep306","volume":"49","author":"TG Rider","year":"2010","unstructured":"Rider TG, Jordan KM (2010) The modern management of gout. Rheumatology 49:5\u201314","journal-title":"Rheumatology"},{"key":"31_CR78","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","volume":"8","author":"G Nuki","year":"2006","unstructured":"Nuki G, Simkin PA (2006) A concise history of gout and hyperuricemia and their treatment. Arthritis Res Therapy 8:S1","journal-title":"Arthritis Res Therapy"},{"key":"31_CR79","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.amjmed.2008.11.013","volume":"122","author":"DE King","year":"2009","unstructured":"King DE, Mainous AG 3rd, Carnemolla M et al (2009) Adherence to healthy lifestyle habits in US adults, 1988\u20132006. Am J Med 122:528\u2013534","journal-title":"Am J Med"},{"key":"31_CR80","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312\u20131324","journal-title":"Ann Rheum Dis"},{"key":"31_CR81","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 46:1372\u20131374","journal-title":"Rheumatology"},{"key":"31_CR82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.amjopharm.2011.07.004","volume":"9","author":"MA Fravel","year":"2011","unstructured":"Fravel MA, Ernst ME (2011) Management of gout in the older adult. Am J Geriatr Pharmacother 9:271\u2013285","journal-title":"Am J Geriatr Pharmacother"},{"key":"31_CR83","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M et al (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545\u2013549","journal-title":"Ann Rheum Dis"},{"key":"31_CR84","first-page":"892","volume":"16","author":"MK Reinders","year":"2008","unstructured":"Reinders MK, Haagsma C, Jansen TL et al (2008) A randomized controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300\u2013600\u00a0mg\/day versus benzbromarone 100\u2013200\u00a0mg\/day in patients with gout. Ann Rheum Dis 16:892\u2013897","journal-title":"Ann Rheum Dis"},{"key":"31_CR85","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/11592750-000000000-00000","volume":"28","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Jordan S (2011) The challenges of gout management in the elderly. Drugs Aging 28:591\u2013603","journal-title":"Drugs Aging"},{"key":"31_CR86","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450\u20132461","journal-title":"N Engl J Med"},{"key":"31_CR87","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/RHU.0b013e31821d352f","volume":"17","author":"K Naoyuki","year":"2011","unstructured":"Naoyuki K, Shin F, Toshikazu H et al (2011) An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol 17:S44\u2013S49","journal-title":"J Clin Rheumatol"},{"key":"31_CR88","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.20680","volume":"64","author":"S Chohan","year":"2012","unstructured":"Chohan S, Becker MA, Macdonald PA et al (2012) Women with gout: the efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res 64:256\u2013261","journal-title":"Arthritis Care Res"},{"key":"31_CR89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1756-185X.2011.01629.x","volume":"14","author":"AP Tran","year":"2011","unstructured":"Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14:33\u201337","journal-title":"Int J Rheum Dis"},{"key":"31_CR90","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, Mysler E, Lin HY et al (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264\u20131271","journal-title":"Ann Rheum Dis"},{"key":"31_CR91","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","volume":"377","author":"CM Burns","year":"2011","unstructured":"Burns CM, Wortmann RL (2011) Gout therapeutics: new drugs for an old disease. Lancet 377:165\u2013177","journal-title":"Lancet"},{"key":"31_CR92","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","volume":"62","author":"S Takahashi","year":"2003","unstructured":"Takahashi S, Moriwaki Y, Yamamoto T et al (2003) Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism. Ann Rheum Dis 62:572\u2013575","journal-title":"Ann Rheum Dis"},{"key":"31_CR93","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","volume":"10","author":"G Nuki","year":"2008","unstructured":"Nuki G (2008) Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 10:218\u2013227","journal-title":"Curr Rheumatol Rep"},{"key":"31_CR94","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/BTH.0b013e3181dcaaa8","volume":"14","author":"M Tripoli","year":"2010","unstructured":"Tripoli M, Falcone AR, Mossuto C et al (2010) Different surgical approaches to treat chronic tophaceous gout in the hand: our experience. Tech Hand Up Extrem Surg 14:187\u2013190","journal-title":"Tech Hand Up Extrem Surg"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-013-0031-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40520-013-0031-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-013-0031-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T07:23:05Z","timestamp":1644736985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40520-013-0031-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,9]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1007\/s40520-013-0031-z","relation":{},"ISSN":["1720-8319","1720-8319"],"issn-type":[{"value":"1720-8319","type":"print"},{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,9]]}}}